- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT02279316
Move for Your Mind - Pilot Trial (MFYM - P)
Home Exercise, Vitamin D and Dalcroze Eurhythmics for Seniors With Mild Cognitive Impairment (MCI) or Mild Dementia
Move for your mind is a single blind, 3-arm randomized controlled clinical pilot trial. The study aims to test the effect of a weekly Dalcroze eurhythmics program (arm 1) and a home strength exercise program (arm 2) against control (no exercise) on the rate of falling, quality of life, gait performance and cognitive function. All groups receive vitamin D. In addition the study shall test the feasibility of the recruitment and the interventions in this target population.
The study includes 60 seniors, age 65 and older, with mild cognitive impairment or mild dementia. Participants are recruited by the memory clinic of City Hospital Waid.
During the 12 months follow-up, participants will have 3 clinical visits (baseline, 6 and 12 month). Despite major efforts the target population is very difficult to recruit and adherence to treatment is low. We therefore decided to stop recruitment and to use this trial as a pilot trial for future clinical trials of the same topic.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Primary objective To test whether the Jaques-Dalcroze eurhythmics program (1 hour a week for 12 months) and/or the simple home exercise program (3 × 30 min a week for 12 months) will decrease rate of falls in seniors with MCI or mild dementia compared with the control group.
Secondary objectives Objective 1: To test whether the Jaques-Dalcroze eurhythmics program (1 hour a week for 12 months) and/or the simple home exercise program (3 × 30 min a week for 12 months) decreases 12-month risk of falling at least once in seniors with MCI or mild dementia compared with the control group.
Objective 2: To test whether the Jaques-Dalcroze eurhythmics program (1 hour a week for 12 months) and/or the simple home exercise program (3 × 30 min a week for 12 months) improves cognitive func-tion and alertness in seniors with MCI or mild dementia compared with the control group.
Objective 3: To test whether the Jaques-Dalcroze eurhythmics program (1 hour a week for 12 months) and/or the simple home exercise program (3 × 30 min a week for 12 months) decreases gait variability in seniors with MCI or mild dementia compared with the control group.
Objective 4: To test whether the Jaques-Dalcroze eurhythmics program (1 hour a week for 12 months) and/or the simple home exercise program (3 × 30 min a week for 12 months) improves quality of life in seniors with MCI or mild dementia compared with the control group.
Tipo de estudio
Inscripción (Actual)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Zurich, Suiza, 8037
- Centre on Aging and Mobility, University of Zurich, Waid City Hospital
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Age 65+ years
- Diagnosed with MCI or mild dementia by the memory clinic of City Hospital Waid
Exclusion Criteria:
-
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Prevención
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Único
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: Jaques-Dalcroze eurhythmics
Jaques-Dalcroze eurhythmics (60min/wk) + 800 IU Vitamin D3
|
All participants receive a dose of 800 IU vitamin D3 per day as a standard of care.
800 IU Vitamin D is the dose that is currently recommended by the Swiss Health Department (Bundesamt für Gesundheit) for seniors over 60.
Otros nombres:
The Jaques-Dalcroze eurhythmics method includes different courses of motion (multi-task exercises) that are conducted to the rhythm of improvised piano music.
A session starts with a short warm-up that includes simple exercises to get body and mind prepared for the rest of the exercise session.
The complexity of the exercises increases gradually during the session: starting with single tasks and then combining them into a multi-task exercise gradually increasing complexity.
|
Experimental: Home exercise program
Home exercise strength program (3x30min/wk) + 800 IU vitamin D
|
All participants receive a dose of 800 IU vitamin D3 per day as a standard of care.
800 IU Vitamin D is the dose that is currently recommended by the Swiss Health Department (Bundesamt für Gesundheit) for seniors over 60.
Otros nombres:
The home exercise program is a strengthening program that will consist of five simple exercises.
|
Otro: Vitamin D only
800 IU Vi-De 3
|
All participants receive a dose of 800 IU vitamin D3 per day as a standard of care.
800 IU Vitamin D is the dose that is currently recommended by the Swiss Health Department (Bundesamt für Gesundheit) for seniors over 60.
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Rate of falls (any falls, low trauma falls, injurious falls) during 12 month follow-up
Periodo de tiempo: at month 2, 4, 6, 8, 10 and 12 after baseline
|
A fall is defined as unintentional coming to rest on the ground, floor, or other lower level (coming to rest against furniture or a wall is not considered a fall).
All reported incident falls will be ascertained every 2 month (phone calls at 2, 4, 8 and 10 months and clinical visits at 6 and 12 months after baseline) with a questionnaire evaluating the circumstances of each fall and injuries associated with it.
Participants will also receive a diary to record any new health event including a fall.
The diary will serve as a supplementary tool to falls evaluation minimizing potential recall bias.
|
at month 2, 4, 6, 8, 10 and 12 after baseline
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Number of participants who fell at least once during 12 months of follow up
Periodo de tiempo: at month 2, 4, 6, 8, 10 and 12 after baseline
|
at month 2, 4, 6, 8, 10 and 12 after baseline
|
|
Gait variability (stride time, stride length and gait speed)
Periodo de tiempo: Baseline, 6 & 12 months
|
assessed by a GAITRite analysis system
|
Baseline, 6 & 12 months
|
Cognitive function
Periodo de tiempo: Baseline, 6 & 12 months
|
assessed using the Montreal Cognitive Assessment (MoCA)
|
Baseline, 6 & 12 months
|
Alertness
Periodo de tiempo: Baseline, 6 & 12 months
|
Alertness will be assessed using the two subtests "alertness" and "split alertness" of the test of attentional performance (TAP)
|
Baseline, 6 & 12 months
|
Quality of life
Periodo de tiempo: Baseline, 6 and 12 months
|
evaluated using the SF-36 questionnaire
|
Baseline, 6 and 12 months
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
progression of MCI/mild dementia
Periodo de tiempo: 6 &12 months
|
any progression of the cognitive disorder to a more severe state ( will be confirmed based on medical records of the memory clinic of Waid City Hospital.
Evaluation of this endpoint will be supported by information from the MoCA and the TAP subtests at baseline, 6, and 12 months clinical visits.
|
6 &12 months
|
Musculoskeletal pain
Periodo de tiempo: baseline, 6 and 12 month
|
assessed using McGill pain map.
Number of painful joints will be assessed using a joint map.
|
baseline, 6 and 12 month
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Heike Bischoff-Ferrari, Prof., Director Geriatric Clinic University Hospital Zurich and Centre on Aging and Mobility, University of Zurich
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Desordenes mentales
- Enfermedades Cerebrales
- Enfermedades del Sistema Nervioso Central
- Enfermedades del Sistema Nervioso
- Trastornos neurocognitivos
- Trastornos cognitivos
- Demencia
- Disfunción congnitiva
- Efectos fisiológicos de las drogas
- Micronutrientes
- Vitaminas
- Agentes de conservación de la densidad ósea
- Hormonas y agentes reguladores del calcio
- Vitamina D
- Colecalciferol
Otros números de identificación del estudio
- SNCTP000000580
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Vi-De 3
-
GlaxoSmithKlineTerminadoEnfermedad Pulmonar Obstructiva CrónicaTaiwán, Tailandia, Porcelana, Filipinas, Corea, república de
-
University of OxfordTerminado
-
Global and Sexual Health (GloSH)Activo, no reclutandoSalud mental | Violencia doméstica | La violencia de pareja | Intervención | Prevención Secundaria | Gestión de problemas más | Ensayo aleatorizado por gruposNepal
-
fan liReclutamiento
-
Istituto Nazionale di Ricovero e Cura per AnzianiTerminado
-
BioMarin PharmaceuticalTerminadoDistrofia muscular de DuchenneBélgica, Países Bajos, Italia, Suecia
-
National University Hospital, SingaporeDesconocidoInsuficiencia de la válvula tricúspide | Síndrome del seno enfermoSingapur
-
Emory UniversityMedtronicTerminadoInsuficiencia cardíaca congestivaEstados Unidos
-
Sanofi Pasteur, a Sanofi CompanyTerminadoInfecciones bacterianas | Fiebre tifoidea | Infecciones por salmonelaJapón
-
Abbott Medical DevicesTerminadoInsuficiencia cardiacaEstados Unidos